{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:11:13Z","timestamp":1793970673978,"version":"4.8.0"},"reference-count":233,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1038\/s41579-022-00770-5","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T08:19:48Z","timestamp":1659687588000},"page":"51-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":483,"title":["Epstein\u2013Barr virus and multiple sclerosis"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6263-519X","authenticated-orcid":false,"given":"Samantha S.","family":"Soldan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3935-9921","authenticated-orcid":false,"given":"Paul M.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"770_CR1","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrc1452","volume":"4","author":"LS Young","year":"2004","unstructured":"Young, L. S. & Rickinson, A. B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4, 757\u2013768 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"770_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc.2016.92","volume":"16","author":"LS Young","year":"2016","unstructured":"Young, L. S., Yap, L. F. & Murray, P. G. Epstein-Barr virus: more than 50 years old and still providing surprises. Nat. Rev. Cancer 16, 789\u2013802 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"770_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03824-y","author":"Y Wong","year":"2021","unstructured":"Wong, Y., Meehan, M. T., Burrows, S. R., Doolan, D. L. & Miles, J. J. Estimating the global burden of Epstein-Barr virus-related cancers. J. Cancer Res. Clin. Oncol. https:\/\/doi.org\/10.1007\/s00432-021-03824-y (2021).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"770_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3389\/fonc.2019.00713","volume":"9","author":"C Shannon-Lowe","year":"2019","unstructured":"Shannon-Lowe, C. & Rickinson, A. The global landscape of EBV-associated tumors. Front. Oncol. 9, 713 (2019).","journal-title":"Front. Oncol."},{"key":"770_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","volume":"102","author":"SK Dunmire","year":"2018","unstructured":"Dunmire, S. K., Verghese, P. S. & Balfour, H. H. Jr. Primary Epstein-Barr virus infection. J. Clin. Virol. 102, 84\u201392 (2018).","journal-title":"J. Clin. Virol."},{"key":"770_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.coi.2021.04.003","volume":"72","author":"B Fournier","year":"2021","unstructured":"Fournier, B. & Latour, S. Immunity to EBV as revealed by immunedeficiencies. Curr. Opin. Immunol. 72, 107\u2013115 (2021).","journal-title":"Curr. Opin. Immunol."},{"key":"770_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1055\/s-0036-1579693","volume":"36","author":"A Ascherio","year":"2016","unstructured":"Ascherio, A. & Munger, K. L. Epidemiology of multiple sclerosis: from risk factors to prevention-an update. Semin. Neurol. 36, 103\u2013114 (2016).","journal-title":"Semin. Neurol."},{"key":"770_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9112191","author":"F Laderach","year":"2021","unstructured":"Laderach, F. & Munz, C. Epstein Barr virus exploits genetic susceptibility to increase multiple sclerosis risk. Microorganisms https:\/\/doi.org\/10.3390\/microorganisms9112191 (2021).","journal-title":"Microorganisms"},{"key":"770_CR9","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton, C. et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult. Scler. 26, 1816\u20131821 (2020).","journal-title":"Mult. Scler."},{"key":"770_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-018-1026-3","volume":"18","author":"R Alroughani","year":"2018","unstructured":"Alroughani, R. & Boyko, A. Pediatric multiple sclerosis: a review. BMC Neurol. 18, 27 (2018).","journal-title":"BMC Neurol."},{"key":"770_CR11","first-page":"183","volume":"36","author":"MM Rodgers","year":"1999","unstructured":"Rodgers, M. M. et al. Gait characteristics of individuals with multiple sclerosis before and after a 6-month aerobic training program. J. Rehabil. Res. Dev. 36, 183\u2013188 (1999).","journal-title":"J. Rehabil. Res. Dev."},{"key":"770_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/B978-0-444-52001-2.00014-5","volume":"122","author":"C Confavreux","year":"2014","unstructured":"Confavreux, C. & Vukusic, S. The clinical course of multiple sclerosis. Handb. Clin. Neurol. 122, 343\u2013369 (2014).","journal-title":"Handb. Clin. Neurol."},{"key":"770_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173 (2018).","journal-title":"Lancet Neurol."},{"key":"770_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","volume":"160","author":"P Brodin","year":"2015","unstructured":"Brodin, P. et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 160, 37\u201347 (2015).","journal-title":"Cell"},{"key":"770_CR15","doi-asserted-by":"crossref","unstructured":"Soldan, S. S. & Jacobson, S. in Neurotropic Viral Infections (ed. Reiss, C.) 175\u2013220 (Springer, 2016).","DOI":"10.1007\/978-3-319-33189-8_6"},{"key":"770_CR16","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/1744666X.2021.1847642","volume":"16","author":"K Ruprecht","year":"2020","unstructured":"Ruprecht, K. The role of Epstein-Barr virus in the etiology of multiple sclerosis: a current review. Expert Rev. Clin. Immunol. 16, 1143\u20131157 (2020).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"770_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","volume":"603","author":"TV Lanz","year":"2022","unstructured":"Lanz, T. V. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 603, 321\u2013327 (2022).","journal-title":"Nature"},{"key":"770_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375, 296\u2013301 (2022).","journal-title":"Science"},{"key":"770_CR19","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41591-022-01823-1","volume":"28","author":"A Bar-Or","year":"2022","unstructured":"Bar-Or, A., Banwell, B., Berger, J. R. & Lieberman, P. M. Guilty by association: Epstein-Barr virus in multiple sclerosis. Nat. Med. 28, 904\u2013906 (2022).","journal-title":"Nat. Med."},{"key":"770_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202\u2013209 (2014).","journal-title":"Nature"},{"key":"770_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/310207a0","volume":"310","author":"R Baer","year":"1984","unstructured":"Baer, R. et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310, 207\u2013211 (1984).","journal-title":"Nature"},{"key":"770_CR22","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/cas.13954","volume":"110","author":"T Kanda","year":"2019","unstructured":"Kanda, T., Yajima, M. & Ikuta, K. Epstein-Barr virus strain variation and cancer. Cancer Sci. 110, 1132\u20131139 (2019).","journal-title":"Cancer Sci."},{"key":"770_CR23","first-page":"151","volume":"390","author":"DA Thorley-Lawson","year":"2015","unstructured":"Thorley-Lawson, D. A. EBV persistence\u2013introducing the virus. Curr. Top. Microbiol. Immunol. 390, 151\u2013209 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"770_CR24","first-page":"45","volume":"390","author":"PJ Farrell","year":"2015","unstructured":"Farrell, P. J. Epstein-Barr virus strain variation. Curr. Top. Microbiol. Immunol. 390, 45\u201369 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"770_CR25","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/gbe\/evu054","volume":"6","author":"G Santpere","year":"2014","unstructured":"Santpere, G. et al. Genome-wide analysis of wild-type Epstein-Barr virus genomes derived from healthy individuals of the 1000 Genomes Project. Genome Biol. Evol. 6, 846\u2013860 (2014).","journal-title":"Genome Biol. Evol."},{"key":"770_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000334693","volume":"55","author":"ML Lay","year":"2012","unstructured":"Lay, M. L. et al. Epstein-Barr virus genotypes and strains in central nervous system demyelinating disease and Epstein-Barr virus-related illnesses in Australia. Intervirology 55, 372\u2013379 (2012).","journal-title":"Intervirology"},{"key":"770_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1177\/1352458510364537","volume":"16","author":"RM Brennan","year":"2010","unstructured":"Brennan, R. M. et al. Strains of Epstein-Barr virus infecting multiple sclerosis patients. Mult. Scler. 16, 643\u2013651 (2010).","journal-title":"Mult. Scler."},{"key":"770_CR28","unstructured":"de-Th\u00e9, G. et al. Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study- a review 3\u201316 (IARC Science Publications, 1975)."},{"key":"770_CR29","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1093\/infdis\/jit321","volume":"208","author":"HH Balfour Jr","year":"2013","unstructured":"Balfour, H. H. Jr. et al. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. J. Infect. Dis. 208, 1286\u20131293 (2013).","journal-title":"J. Infect. Dis."},{"key":"770_CR30","unstructured":"Chandran, B. & Hutt-Fletcher, L. in Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis (eds Arvin, A. et al.) (Cambridge Univ. Press, 2007)."},{"key":"770_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/35095584","volume":"1","author":"DA Thorley-Lawson","year":"2001","unstructured":"Thorley-Lawson, D. A. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1, 75\u201382 (2001).","journal-title":"Nat. Rev. Immunol."},{"key":"770_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1158\/1078-0432.CCR-0670-3","volume":"10","author":"MP Thompson","year":"2004","unstructured":"Thompson, M. P. & Kurzrock, R. Epstein-Barr virus and cancer. Clin. Cancer Res. 10, 803\u2013821 (2004).","journal-title":"Clin. Cancer Res."},{"key":"770_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192109","volume":"13","author":"A Hassani","year":"2018","unstructured":"Hassani, A., Corboy, J. R., Al-Salam, S. & Khan, G. Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLoS ONE 13, e0192109 (2018).","journal-title":"PLoS ONE"},{"key":"770_CR34","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1097\/QAD.0000000000001579","volume":"31","author":"S Gianella","year":"2017","unstructured":"Gianella, S. et al. Effect of cytomegalovirus and Epstein-Barr virus replication on intestinal mucosal gene expression and microbiome composition of HIV-infected and uninfected individuals. AIDS 31, 2059\u20132067 (2017).","journal-title":"AIDS"},{"key":"770_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/viro.2000.0624","volume":"277","author":"P Speck","year":"2000","unstructured":"Speck, P., Haan, K. M. & Longnecker, R. Epstein-Barr virus entry into cells. Virology 277, 1\u20135 (2000).","journal-title":"Virology"},{"key":"770_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.virol.2006.09.047","volume":"359","author":"J Xiao","year":"2007","unstructured":"Xiao, J., Palefsky, J. M., Herrera, R. & Tugizov, S. M. Characterization of the Epstein-Barr virus glycoprotein BMRF-2. Virology 359, 382\u2013396 (2007).","journal-title":"Virology"},{"key":"770_CR37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.virol.2009.03.030","volume":"388","author":"J Xiao","year":"2009","unstructured":"Xiao, J., Palefsky, J. M., Herrera, R., Berline, J. & Tugizov, S. M. EBV BMRF-2 facilitates cell-to-cell spread of virus within polarized oral epithelial cells. Virology 388, 335\u2013343 (2009).","journal-title":"Virology"},{"key":"770_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41564-017-0080-8","volume":"3","author":"H Zhang","year":"2018","unstructured":"Zhang, H. et al. Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry. Nat. Microbiol. 3, 1\u20138 (2018).","journal-title":"Nat. Microbiol."},{"key":"770_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13010","volume":"21","author":"RJ Stubbins","year":"2019","unstructured":"Stubbins, R. J. et al. Epstein-Barr virus associated smooth muscle tumors in solid organ transplant recipients: incidence over 31 years at a single institution and review of the literature. Transpl. Infect. Dis. 21, e13010 (2019).","journal-title":"Transpl. Infect. Dis."},{"key":"770_CR40","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.3389\/fimmu.2017.01867","volume":"8","author":"H Kimura","year":"2017","unstructured":"Kimura, H. & Cohen, J. I. Chronic active Epstein-Barr virus disease. Front. Immunol. 8, 1867 (2017).","journal-title":"Front. Immunol."},{"key":"770_CR41","doi-asserted-by":"publisher","first-page":"e01844","DOI":"10.1128\/mBio.01844-15","volume":"6","author":"HC Jha","year":"2015","unstructured":"Jha, H. C. et al. Gammaherpesvirus infection of human neuronal cells. mBio 6, e01844\u2013e01815 (2015).","journal-title":"mBio"},{"key":"770_CR42","doi-asserted-by":"publisher","first-page":"7722","DOI":"10.1128\/JVI.73.9.7722-7733.1999","volume":"73","author":"A Menet","year":"1999","unstructured":"Menet, A. et al. Epstein-Barr virus infection of human astrocyte cell lines. J. Virol. 73, 7722\u20137733 (1999).","journal-title":"J. Virol."},{"key":"770_CR43","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/978-981-10-7230-7_17","volume":"1045","author":"T Kanda","year":"2018","unstructured":"Kanda, T. EBV-encoded latent genes. Adv. Exp. Med. Biol. 1045, 377\u2013394 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"770_CR44","unstructured":"Kieff, E. & Rickinson, A. B. in Fields Virology (eds Knipe, D. M. & Howley, P. M.) 2603\u20132654 (Lippincott Williams and Wilkins, 2007)."},{"key":"770_CR45","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3892\/ijo.2015.2856","volume":"46","author":"A Shinozaki-Ushiku","year":"2015","unstructured":"Shinozaki-Ushiku, A., Kunita, A. & Fukayama, M. Update on Epstein-Barr virus and gastric cancer (review). Int. J. Oncol. 46, 1421\u20131434 (2015).","journal-title":"Int. J. Oncol."},{"key":"770_CR46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/odi.12393","volume":"22","author":"JS Greenspan","year":"2016","unstructured":"Greenspan, J. S., Greenspan, D. & Webster-Cyriaque, J. Hairy leukoplakia; lessons learned: 30-plus years. Oral Dis. 22, 120\u2013127 (2016).","journal-title":"Oral Dis."},{"key":"770_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/v13122344","author":"T Murata","year":"2021","unstructured":"Murata, T. et al. Molecular basis of Epstein-Barr virus latency establishment and lytic reactivation. Viruses https:\/\/doi.org\/10.3390\/v13122344 (2021).","journal-title":"Viruses"},{"key":"770_CR48","first-page":"237","volume":"391","author":"J McKenzie","year":"2015","unstructured":"McKenzie, J. & El-Guindy, A. Epstein-Barr virus lytic cycle reactivation. Curr. Top. Microbiol. Immunol. 391, 237\u2013261 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"770_CR49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/BF00053132","volume":"2","author":"CK Chan","year":"1991","unstructured":"Chan, C. K. et al. Epstein-Barr virus antibody patterns preceding the diagnosis of nasopharyngeal carcinoma. Cancer Causes Control. 2, 125\u2013131 (1991).","journal-title":"Cancer Causes Control."},{"key":"770_CR50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/ijc.2910490313","volume":"49","author":"N Mueller","year":"1991","unstructured":"Mueller, N. et al. Epstein-Barr virus antibody patterns preceding the diagnosis of non-Hodgkin\u2019s lymphoma. Int. J. Cancer 49, 387\u2013393 (1991).","journal-title":"Int. J. Cancer"},{"key":"770_CR51","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00088-21","volume":"95","author":"F Lu","year":"2021","unstructured":"Lu, F. et al. Defective Epstein-Barr virus genomes and atypical viral gene expression in B-cell lines derived from multiple myeloma patients. J. Virol. 95, e0008821 (2021).","journal-title":"J. Virol."},{"key":"770_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111824","author":"Q Rosemarie","year":"2020","unstructured":"Rosemarie, Q. & Sugden, B. Epstein-Barr virus: how its lytic phase contributes to oncogenesis. Microorganisms https:\/\/doi.org\/10.3390\/microorganisms8111824 (2020).","journal-title":"Microorganisms"},{"key":"770_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030487","author":"PAC Maple","year":"2020","unstructured":"Maple, P. A. C., Gran, B., Tanasescu, R., Pritchard, D. I. & Constantinescu, C. S. An absence of Epstein-Barr virus reactivation and associations with disease activity in people with multiple sclerosis undergoing therapeutic hookworm vaccination. Vaccines https:\/\/doi.org\/10.3390\/vaccines8030487 (2020).","journal-title":"Vaccines"},{"key":"770_CR54","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1468-1331.2007.02009.x","volume":"15","author":"O Torkildsen","year":"2008","unstructured":"Torkildsen, O., Nyland, H., Myrmel, H. & Myhr, K. M. Epstein-Barr virus reactivation and multiple sclerosis. Eur. J. Neurol. 15, 106\u2013108 (2008).","journal-title":"Eur. J. Neurol."},{"key":"770_CR55","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1212\/WNL.0b013e3182a841e4","volume":"81","author":"C Yea","year":"2013","unstructured":"Yea, C. et al. Epstein-Barr virus in oral shedding of children with multiple sclerosis. Neurology 81, 1392\u20131399 (2013).","journal-title":"Neurology"},{"key":"770_CR56","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ddmod.2020.01.001","volume":"32","author":"SS Soldan","year":"2020","unstructured":"Soldan, S. S. & Lieberman, P. M. Epstein-Barr virus infection in the development of neurological disorders. Drug Discov. Today Dis. Model. 32, 35\u201352 (2020).","journal-title":"Drug Discov. Today Dis. Model."},{"key":"770_CR57","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","volume":"17","author":"C Munz","year":"2019","unstructured":"Munz, C. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat. Rev. Microbiol. 17, 691\u2013700 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"770_CR58","doi-asserted-by":"publisher","first-page":"8649","DOI":"10.1128\/JVI.75.18.8649-8659.2001","volume":"75","author":"A Leen","year":"2001","unstructured":"Leen, A. et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4+ T-helper 1 responses. J. Virol. 75, 8649\u20138659 (2001).","journal-title":"J. Virol."},{"key":"770_CR59","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1172\/JCI10209","volume":"107","author":"K Bickham","year":"2001","unstructured":"Bickham, K. et al. EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J. Clin. Invest. 107, 121\u2013130 (2001).","journal-title":"J. Clin. Invest."},{"key":"770_CR60","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1084\/jem.191.10.1649","volume":"191","author":"C Munz","year":"2000","unstructured":"Munz, C. et al. Human CD4+ T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med. 191, 1649\u20131660 (2000).","journal-title":"J. Exp. Med."},{"key":"770_CR61","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1182\/blood-2014-01-553024","volume":"124","author":"T Azzi","year":"2014","unstructured":"Azzi, T. et al. Role for early-differentiated natural killer cells in infectious mononucleosis. Blood 124, 2533\u20132543 (2014).","journal-title":"Blood"},{"key":"770_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005286","volume":"11","author":"SK Dunmire","year":"2015","unstructured":"Dunmire, S. K., Grimm, J. M., Schmeling, D. O., Balfour, H. H. Jr & Hogquist, K. A. The incubation period of primary Epstein-Barr virus infection: viral dynamics and immunologic events. PLoS Pathog. 11, e1005286 (2015).","journal-title":"PLoS Pathog."},{"key":"770_CR63","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1365-2141.2005.05452.x","volume":"129","author":"H Williams","year":"2005","unstructured":"Williams, H. et al. The immune response to primary EBV infection: a role for natural killer cells. Br. J. Haematol. 129, 266\u2013274 (2005).","journal-title":"Br. J. Haematol."},{"key":"770_CR64","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1084\/jem.20081720","volume":"206","author":"T Strowig","year":"2009","unstructured":"Strowig, T. et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J. Exp. Med. 206, 1423\u20131434 (2009).","journal-title":"J. Exp. Med."},{"key":"770_CR65","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.celrep.2013.11.041","volume":"5","author":"O Chijioke","year":"2013","unstructured":"Chijioke, O. et al. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. Cell Rep. 5, 1489\u20131498 (2013).","journal-title":"Cell Rep."},{"key":"770_CR66","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93179","author":"NA Zumwalde","year":"2017","unstructured":"Zumwalde, N. A. et al. Adoptively transferred V\u03b39V\u03b42 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.93179 (2017).","journal-title":"JCI Insight"},{"key":"770_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194752","author":"CNR Lino","year":"2021","unstructured":"Lino, C. N. R. & Ghosh, S. Epstein-Barr virus in inborn immunodeficiency-more than infection. Cancers https:\/\/doi.org\/10.3390\/cancers13194752 (2021).","journal-title":"Cancers"},{"key":"770_CR68","first-page":"241","volume":"390","author":"JI Cohen","year":"2015","unstructured":"Cohen, J. I. Primary immunodeficiencies associated with EBV disease. Curr. Top. Microbiol. Immunol. 390, 241\u2013265 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"770_CR69","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001588","author":"S Huo","year":"2020","unstructured":"Huo, S. et al. EBV-EBNA1 constructs an immunosuppressive microenvironment for nasopharyngeal carcinoma by promoting the chemoattraction of Treg cells. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-001588 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"770_CR70","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02243-21","volume":"12","author":"D Westhoff Smith","year":"2021","unstructured":"Westhoff Smith, D., Chakravorty, A., Hayes, M., Hammerschmidt, W. & Sugden, B. The Epstein-Barr virus oncogene EBNA1 suppresses natural killer cell responses and apoptosis early after infection of peripheral B cells. mBio 12, e0224321 (2021).","journal-title":"mBio"},{"key":"770_CR71","doi-asserted-by":"publisher","first-page":"103572","DOI":"10.1016\/j.ebiom.2021.103572","volume":"71","author":"JT Keane","year":"2021","unstructured":"Keane, J. T. et al. The interaction of Epstein-Barr virus encoded transcription factor EBNA2 with multiple sclerosis risk loci is dependent on the risk genotype. EBioMedicine 71, 103572 (2021).","journal-title":"EBioMedicine"},{"key":"770_CR72","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1099\/vir.0.82128-0","volume":"87","author":"LC Spender","year":"2006","unstructured":"Spender, L. C. et al. Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells. J. Gen. Virol. 87, 2859\u20132867 (2006).","journal-title":"J. Gen. Virol."},{"key":"770_CR73","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1182\/blood-2004-08-3196","volume":"105","author":"F Pages","year":"2005","unstructured":"Pages, F. et al. Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood 105, 1632\u20131639 (2005).","journal-title":"Blood"},{"key":"770_CR74","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41375-018-0178-x","volume":"33","author":"E Anastasiadou","year":"2019","unstructured":"Anastasiadou, E. et al. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia 33, 132\u2013147 (2019).","journal-title":"Leukemia"},{"key":"770_CR75","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.virol.2021.02.004","volume":"557","author":"Y Yanagi","year":"2021","unstructured":"Yanagi, Y. et al. RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells. Virology 557, 44\u201354 (2021).","journal-title":"Virology"},{"key":"770_CR76","first-page":"4930","volume":"12","author":"K Kanda","year":"1992","unstructured":"Kanda, K. et al. The EBNA2-related resistance towards alpha interferon (IFN-alpha) in Burkitt\u2019s lymphoma cells effects induction of IFN-induced genes but not the activation of transcription factor ISGF-3. Mol. Cell Biol. 12, 4930\u20134936 (1992).","journal-title":"Mol. Cell Biol."},{"key":"770_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009834","volume":"17","author":"C Su","year":"2021","unstructured":"Su, C. et al. EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes. PLoS Pathog. 17, e1009834 (2021).","journal-title":"PLoS Pathog."},{"key":"770_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002704","volume":"8","author":"S Jochum","year":"2012","unstructured":"Jochum, S., Moosmann, A., Lang, S., Hammerschmidt, W. & Zeidler, R. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS Pathog. 8, e1002704 (2012).","journal-title":"PLoS Pathog."},{"key":"770_CR79","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03440-20","author":"M Bouvet","year":"2021","unstructured":"Bouvet, M. et al. Multiple viral microRNAs regulate interferon release and signaling early during infection with Epstein-Barr virus. mBio https:\/\/doi.org\/10.1128\/mBio.03440-20 (2021).","journal-title":"mBio"},{"key":"770_CR80","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01941-18","author":"A Murer","year":"2019","unstructured":"Murer, A. et al. MicroRNAs of Epstein-Barr virus attenuate T-cell-mediated immune control in vivo. mBio https:\/\/doi.org\/10.1128\/mBio.01941-18 (2019).","journal-title":"mBio"},{"key":"770_CR81","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ana.410340313","volume":"34","author":"N Joshi","year":"1993","unstructured":"Joshi, N., Usuku, K. & Hauser, S. L. The T-cell response to myelin basic protein in familial multiple sclerosis: diversity of fine specificity, restricting elements, and T-cell receptor usage. Ann. Neurol. 34, 385\u2013393 (1993).","journal-title":"Ann. Neurol."},{"key":"770_CR82","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1600-0404.1997.tb00210.x","volume":"95","author":"C Martin","year":"1997","unstructured":"Martin, C. et al. Absence of seven human herpesviruses, including HHV-6, by polymerase chain reaction in CSF and blood from patients with multiple sclerosis and optic neuritis. Acta Neurol. Scand. 95, 280\u2013283 (1997).","journal-title":"Acta Neurol. Scand."},{"key":"770_CR83","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0165-5728(94)90233-X","volume":"54","author":"CJ Sindic","year":"1994","unstructured":"Sindic, C. J., Monteyne, P. & Laterre, E. C. The intrathecal synthesis of virus-specific oligoclonal IgG in multiple sclerosis. J. Neuroimmunol. 54, 75\u201380 (1994).","journal-title":"J. Neuroimmunol."},{"key":"770_CR84","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/1531-8249(199907)46:1<6::AID-ANA4>3.0.CO;2-M","volume":"46","author":"S Sriram","year":"1999","unstructured":"Sriram, S. et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann. Neurol. 46, 6\u201314 (1999).","journal-title":"Ann. Neurol."},{"key":"770_CR85","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/1352458513490545","volume":"20","author":"JO Virtanen","year":"2014","unstructured":"Virtanen, J. O., Wohler, J., Fenton, K., Reich, D. S. & Jacobson, S. Oligoclonal bands in multiple sclerosis reactive against two herpesviruses and association with magnetic resonance imaging findings. Mult. Scler. 20, 27\u201334 (2014).","journal-title":"Mult. Scler."},{"key":"770_CR86","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jneuroim.2010.10.027","volume":"230","author":"D Franciotta","year":"2011","unstructured":"Franciotta, D. et al. Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases. J. Neuroimmunol. 230, 160\u2013163 (2011).","journal-title":"J. Neuroimmunol."},{"key":"770_CR87","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s11481-020-09948-1","volume":"16","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Antibodies from multiple sclerosis brain identified Epstein-Barr virus nuclear antigen 1 & 2 epitopes which are recognized by oligoclonal bands. J. Neuroimmune Pharmacol. 16, 567\u2013580 (2021).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"770_CR88","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/1352458515588581","volume":"22","author":"GP van Nierop","year":"2016","unstructured":"van Nierop, G. P., Mautner, J., Mitterreiter, J. G., Hintzen, R. Q. & Verjans, G. M. Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins. Mult. Scler. 22, 279\u2013291 (2016).","journal-title":"Mult. Scler."},{"key":"770_CR89","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1126\/science.1062960","volume":"294","author":"D Chabas","year":"2001","unstructured":"Chabas, D. et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294, 1731\u20131735 (2001).","journal-title":"Science"},{"key":"770_CR90","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","volume":"17","author":"MT Cencioni","year":"2021","unstructured":"Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A. & Muraro, P. A. B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. Nat. Rev. Neurol. 17, 399\u2013414 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"770_CR91","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jneuroim.2017.05.004","volume":"309","author":"RP Lisak","year":"2017","unstructured":"Lisak, R. P. et al. B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro. J. Neuroimmunol. 309, 88\u201399 (2017).","journal-title":"J. Neuroimmunol."},{"key":"770_CR92","doi-asserted-by":"publisher","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","volume":"7","author":"R Li","year":"2015","unstructured":"Li, R. et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci. Transl. Med. 7, 310ra166 (2015).","journal-title":"Sci. Transl. Med."},{"key":"770_CR93","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1212\/WNL.37.7.1097","volume":"37","author":"HS Panitch","year":"1987","unstructured":"Panitch, H. S., Hirsch, R. L., Schindler, J. & Johnson, K. P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37, 1097\u20131102 (1987).","journal-title":"Neurology"},{"key":"770_CR94","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0165-5728(02)00182-0","volume":"129","author":"X Feng","year":"2002","unstructured":"Feng, X. et al. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J. Neuroimmunol. 129, 205\u2013215 (2002).","journal-title":"J. Neuroimmunol."},{"key":"770_CR95","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","volume":"47","author":"C Lucchinetti","year":"2000","unstructured":"Lucchinetti, C. et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707\u2013717 (2000).","journal-title":"Ann. Neurol."},{"key":"770_CR96","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028936","author":"H Lassmann","year":"2018","unstructured":"Lassmann, H. Multiple sclerosis pathology. Cold Spring Harb. Perspect. Med. https:\/\/doi.org\/10.1101\/cshperspect.a028936 (2018).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"770_CR97","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ana.20016","volume":"55","author":"MH Barnett","year":"2004","unstructured":"Barnett, M. H. & Prineas, J. W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55, 458\u2013468 (2004).","journal-title":"Ann. Neurol."},{"key":"770_CR98","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fimmu.2015.00604","volume":"6","author":"M Salou","year":"2015","unstructured":"Salou, M., Nicol, B., Garcia, A. & Laplaud, D. A. Involvement of CD8+ T cells in multiple sclerosis. Front. Immunol. 6, 604 (2015).","journal-title":"Front. Immunol."},{"key":"770_CR99","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/acn3.199","volume":"2","author":"M Salou","year":"2015","unstructured":"Salou, M. et al. Expanded CD8 T-cell sharing between periphery and CNS in multiple sclerosis. Ann. Clin. Transl. Neurol. 2, 609\u2013622 (2015).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"770_CR100","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.1025","author":"A Cagol","year":"2022","unstructured":"Cagol, A. et al. Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2022.1025 (2022).","journal-title":"JAMA Neurol."},{"key":"770_CR101","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00281-021-00907-3","volume":"4","author":"W Kim","year":"2022","unstructured":"Kim, W. & Patsopoulos, N. A. Genetics and functional genomics of multiple sclerosis. Semin. Immunopathol. 4, 63\u201379 (2022).","journal-title":"Semin. Immunopathol."},{"key":"770_CR102","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s00415-020-10119-8","volume":"268","author":"S Yuan","year":"2021","unstructured":"Yuan, S., Xiong, Y. & Larsson, S. C. An atlas on risk factors for multiple sclerosis: a Mendelian randomization study. J. Neurol. 268, 114\u2013124 (2021).","journal-title":"J. Neurol."},{"key":"770_CR103","first-page":"148","volume":"22","author":"C Jersild","year":"1975","unstructured":"Jersild, C., Dupont, B., Fog, T., Platz, P. J. & Svejgaard, A. Histocompatibility determinants in multiple sclerosis. Transplant. Rev. 22, 148\u2013163 (1975).","journal-title":"Transplant. Rev."},{"key":"770_CR104","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/135245859700300606","volume":"3","author":"SD Cook","year":"1997","unstructured":"Cook, S. D. Multiple sclerosis and viruses. Mult. Scler. 3, 388\u2013389 (1997).","journal-title":"Mult. Scler."},{"key":"770_CR105","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/ng.396","volume":"41","author":"AustraliaNew Zealand Multiple Scler","year":"2009","unstructured":"Australia & New Zealand Multiple Sclerosis Genetics Consortium. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat. Genet. 41, 824\u2013828 (2009).","journal-title":"Nat. Genet."},{"key":"770_CR106","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/ng.401","volume":"41","author":"PL De Jager","year":"2009","unstructured":"De Jager, P. L. et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 41, 776\u2013782 (2009).","journal-title":"Nat. Genet."},{"key":"770_CR107","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa073493","volume":"357","author":"International Multiple Sclerosis Genetics Consortium","year":"2007","unstructured":"International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357, 851\u2013862 (2007).","journal-title":"N. Engl. J. Med."},{"key":"770_CR108","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/B978-0-444-52001-2.00009-1","volume":"122","author":"BA Cree","year":"2014","unstructured":"Cree, B. A. Multiple sclerosis genetics. Handb. Clin. Neurol. 122, 193\u2013209 (2014).","journal-title":"Handb. Clin. Neurol."},{"key":"770_CR109","doi-asserted-by":"crossref","unstructured":"Lin, X., Deng, F. Y., Lu, X. & Lei, S. F. Susceptibility genes for multiple sclerosis identified in a gene-based genome-wide association study. J. Clin. Neurol. (2015).","DOI":"10.3988\/jcn.2015.11.4.311"},{"key":"770_CR110","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1600-0404.1998.tb00608.x","volume":"97","author":"B He","year":"1998","unstructured":"He, B., Yang, B., Lundahl, J., Fredrikson, S. & Hillert, J. The myelin basic protein gene in multiple sclerosis: identification of discrete alleles of a 1.3 kb tetranucleotide repeat sequence. Acta Neurol. Scand. 97, 46\u201351 (1998).","journal-title":"Acta Neurol. Scand."},{"key":"770_CR111","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/ana.410360121","volume":"36","author":"H Kellar-Wood","year":"1994","unstructured":"Kellar-Wood, H., Robertson, N., Govan, G. G., Compston, D. A. & Harding, A. E. Leber\u2019s hereditary optic neuropathy mitochondrial DNA mutations in multiple sclerosis. Ann. Neurol. 36, 109\u2013112 (1994).","journal-title":"Ann. Neurol."},{"key":"770_CR112","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/sj.ejhg.5200293","volume":"7","author":"P Reynier","year":"1999","unstructured":"Reynier, P. et al. mtDNA haplogroup J: a contributing factor of optic neuritis. Eur. J. Hum. Genet. 7, 404\u2013406 (1999).","journal-title":"Eur. J. Hum. Genet."},{"key":"770_CR113","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/135245859600200501","volume":"2","author":"RJ Thompson","year":"1996","unstructured":"Thompson, R. J. et al. Analysis of polymorphisms of the 2\u2019,3\u2019-cyclic nucleotide-3\u2019-phosphodiesterase gene in patients with multiple sclerosis. Mult. Scler. 2, 215\u2013221 (1996).","journal-title":"Mult. Scler."},{"key":"770_CR114","doi-asserted-by":"publisher","first-page":"eabo7799","DOI":"10.1126\/sciimmunol.abo7799","volume":"7","author":"LM Sollid","year":"2022","unstructured":"Sollid, L. M. Epstein-Barr virus as a driver of multiple sclerosis. Sci. Immunol. 7, eabo7799 (2022).","journal-title":"Sci. Immunol."},{"key":"770_CR115","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/0092-8674(95)90348-8","volume":"80","author":"KW Wucherpfennig","year":"1995","unstructured":"Wucherpfennig, K. W. & Strominger, J. L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80, 695\u2013705 (1995).","journal-title":"Cell"},{"key":"770_CR116","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1084\/jem.20072397","volume":"205","author":"JD Lunemann","year":"2008","unstructured":"Lunemann, J. D. et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J. Exp. Med. 205, 1763\u20131773 (2008).","journal-title":"J. Exp. Med."},{"key":"770_CR117","doi-asserted-by":"publisher","first-page":"16955","DOI":"10.1073\/pnas.1902623116","volume":"116","author":"K Tengvall","year":"2019","unstructured":"Tengvall, K. et al. Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. Proc. Natl Acad. Sci. USA 116, 16955\u201316960 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"770_CR118","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4049\/jimmunol.162.1.129","volume":"162","author":"AC van Sechel","year":"1999","unstructured":"van Sechel, A. C. et al. EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J. Immunol. 162, 129\u2013135 (1999).","journal-title":"J. Immunol."},{"key":"770_CR119","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","volume":"175","author":"I Jelcic","year":"2018","unstructured":"Jelcic, I. et al. Memory B cells activate brain-homing, autoreactive CD4(+) T cells in multiple sclerosis. Cell 175, 85\u2013100 e123 (2018).","journal-title":"Cell"},{"key":"770_CR120","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jneuroim.2010.04.007","volume":"225","author":"V Nociti","year":"2010","unstructured":"Nociti, V. et al. Epstein-Barr virus antibodies in serum and cerebrospinal fluid from multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy and amyotrophic lateral sclerosis. J. Neuroimmunol. 225, 149\u2013152 (2010).","journal-title":"J. Neuroimmunol."},{"key":"770_CR121","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nrneurol.2012.198","volume":"8","author":"A Ascherio","year":"2012","unstructured":"Ascherio, A., Munger, K. L. & Lunemann, J. D. The initiation and prevention of multiple sclerosis. Nat. Rev. Neurol. 8, 602\u2013612 (2012).","journal-title":"Nat. Rev. Neurol."},{"key":"770_CR122","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1212\/WNL.0b013e3181aa2a5f","volume":"73","author":"JD Lunemann","year":"2009","unstructured":"Lunemann, J. D. & Ascherio, A. Immune responses to EBNA1: biomarkers in MS. Neurology 73, 13\u201314 (2009).","journal-title":"Neurology"},{"key":"770_CR123","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000872","author":"JY Mescheriakova","year":"2020","unstructured":"Mescheriakova, J. Y., van Nierop, G. P., van der Eijk, A. A., Kreft, K. L. & Hintzen, R. Q. EBNA-1 titer gradient in families with multiple sclerosis indicates a genetic contribution. Neurol. Neuroimmunol. Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000872 (2020).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"770_CR124","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3389\/fneur.2019.01368","volume":"10","author":"AK Hedstr\u00f6m","year":"2019","unstructured":"Hedstr\u00f6m, A. K. et al. High levels of Epstein-Barr virus nuclear antigen-1-specific antibodies and infectious mononucleosis act both independently and synergistically to increase multiple sclerosis risk. Front. Neurol. 10, 1368 (2019).","journal-title":"Front. Neurol."},{"key":"770_CR125","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0165-5728(00)00181-8","volume":"105","author":"JM van Noort","year":"2000","unstructured":"van Noort, J. M., Bajramovic, J. J., Plomp, A. C. & van Stipdonk, M. J. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J. Neuroimmunol. 105, 46\u201357 (2000).","journal-title":"J. Neuroimmunol."},{"key":"770_CR126","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1074\/mcp.M115.051664","volume":"15","author":"M Hecker","year":"2016","unstructured":"Hecker, M. et al. High-density peptide microarray analysis of IgG autoantibody reactivities in serum and cerebrospinal fluid of multiple sclerosis patients. Mol. Cell Proteom. 15, 1360\u20131380 (2016).","journal-title":"Mol. Cell Proteom."},{"key":"770_CR127","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/2049-632X.12066","volume":"69","author":"G Capone","year":"2013","unstructured":"Capone, G. et al. Peptide matching between Epstein-Barr virus and human proteins. Pathog. Dis. 69, 205\u2013212 (2013).","journal-title":"Pathog. Dis."},{"key":"770_CR128","doi-asserted-by":"publisher","first-page":"757302","DOI":"10.3389\/fimmu.2021.757302","volume":"12","author":"UC Meier","year":"2021","unstructured":"Meier, U. C., Cipian, R. C., Karimi, A., Ramasamy, R. & Middeldorp, J. M. Cumulative roles for Epstein-Barr virus, human endogenous retroviruses, and human herpes virus-6 in driving an inflammatory cascade underlying MS pathogenesis. Front. Immunol. 12, 757302 (2021).","journal-title":"Front. Immunol."},{"key":"770_CR129","first-page":"23","volume":"269","author":"NP Dantuma","year":"2002","unstructured":"Dantuma, N. P., Sharipo, A. & Masucci, M. G. Avoiding proteasomal processing: the case of EBNA1. Curr. Top. Microbiol. Immunol. 269, 23\u201336 (2002).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"770_CR130","doi-asserted-by":"publisher","first-page":"12616","DOI":"10.1073\/pnas.94.23.12616","volume":"94","author":"J Levitskaya","year":"1997","unstructured":"Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A. & Masucci, M. G. Inhibition of ubiquitin\/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl Acad. Sci. USA 94, 12616\u201312621 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"770_CR131","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/375685a0","volume":"375","author":"J Levitskaya","year":"1995","unstructured":"Levitskaya, J. et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375, 685\u2013688 (1995).","journal-title":"Nature"},{"key":"770_CR132","doi-asserted-by":"publisher","first-page":"104484","DOI":"10.1016\/j.cellimm.2022.104484","volume":"374","author":"MC Tovar Fernandez","year":"2022","unstructured":"Tovar Fernandez, M. C. et al. Substrate-specific presentation of MHC class I-restricted antigens via autophagy pathway. Cell Immunol. 374, 104484 (2022).","journal-title":"Cell Immunol."},{"key":"770_CR133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001151","volume":"6","author":"S Apcher","year":"2010","unstructured":"Apcher, S., Daskalogianni, C., Manoury, B. & Fahraeus, R. Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation. PLoS Pathog. 6, e1001151 (2010).","journal-title":"PLoS Pathog."},{"key":"770_CR134","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004423","volume":"10","author":"JT Tellam","year":"2014","unstructured":"Tellam, J. T. et al. mRNA Structural constraints on EBNA1 synthesis impact on in vivo antigen presentation and early priming of CD8+ T cells. PLoS Pathog. 10, e1004423 (2014).","journal-title":"PLoS Pathog."},{"key":"770_CR135","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nchembio.1479","volume":"10","author":"P Murat","year":"2014","unstructured":"Murat, P. et al. G-quadruplexes regulate Epstein-Barr virus-encoded nuclear antigen 1 mRNA translation. Nat. Chem. Biol. 10, 358\u2013364 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"770_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003112","volume":"8","author":"JT Tellam","year":"2012","unstructured":"Tellam, J. T., Lekieffre, L., Zhong, J., Lynn, D. J. & Khanna, R. Messenger RNA sequence rather than protein sequence determines the level of self-synthesis and antigen presentation of the EBV-encoded antigen, EBNA1. PLoS Pathog. 8, e1003112 (2012).","journal-title":"PLoS Pathog."},{"key":"770_CR137","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/1073858410381531","volume":"17","author":"MP Pender","year":"2011","unstructured":"Pender, M. P. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 17, 351\u2013367 (2011).","journal-title":"Neuroscientist"},{"key":"770_CR138","first-page":"1","volume":"305","author":"F Melchers","year":"2006","unstructured":"Melchers, F. & Rolink, A. R. B cell tolerance\u2013how to make it and how to break it. Curr. Top. Microbiol. Immunol. 305, 1\u201323 (2006).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"770_CR139","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","volume":"35","author":"MA Weniger","year":"2021","unstructured":"Weniger, M. A. & Kuppers, R. Molecular biology of Hodgkin lymphoma. Leukemia 35, 968\u2013981 (2021).","journal-title":"Leukemia"},{"key":"770_CR140","doi-asserted-by":"publisher","first-page":"14421","DOI":"10.1073\/pnas.1921139117","volume":"117","author":"T Sommermann","year":"2020","unstructured":"Sommermann, T. et al. Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis. Proc. Natl Acad. Sci. USA 117, 14421\u201314432 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"770_CR141","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.msard.2017.05.009","volume":"16","author":"M Laurence","year":"2017","unstructured":"Laurence, M. & Benito-Leon, J. Epstein-Barr virus and multiple sclerosis: updating Pender\u2019s hypothesis. Mult. Scler. Relat. Disord. 16, 8\u201314 (2017).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"770_CR142","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-020-03075-w","volume":"590","author":"IK Choi","year":"2021","unstructured":"Choi, I. K. et al. Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature 590, 157\u2013162 (2021).","journal-title":"Nature"},{"key":"770_CR143","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood.2020009482","volume":"137","author":"Y Deng","year":"2021","unstructured":"Deng, Y. et al. CD27 is required for protective lytic EBV antigen-specific CD8+ T-cell expansion. Blood 137, 3225\u20133236 (2021).","journal-title":"Blood"},{"key":"770_CR144","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12974-017-1049-5","volume":"15","author":"C Veroni","year":"2018","unstructured":"Veroni, C., Serafini, B., Rosicarelli, B., Fagnani, C. & Aloisi, F. Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis. J. Neuroinflamm. 15, 18 (2018).","journal-title":"J. Neuroinflamm."},{"key":"770_CR145","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/NEN.0b013e31827bfc62","volume":"72","author":"R Magliozzi","year":"2013","unstructured":"Magliozzi, R. et al. B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J. Neuropathol. Exp. Neurol. 72, 29\u201341 (2013).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"770_CR146","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/NEN.0b013e3181e332ec","volume":"69","author":"B Serafini","year":"2010","unstructured":"Serafini, B. et al. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J. Neuropathol. Exp. Neurol. 69, 677\u2013693 (2010).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"770_CR147","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1212\/WNL.0b013e31823ed057","volume":"78","author":"JS Tzartos","year":"2012","unstructured":"Tzartos, J. S. et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 78, 15\u201323 (2012).","journal-title":"Neurology"},{"key":"770_CR148","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000466","volume":"5","author":"MA Moreno","year":"2018","unstructured":"Moreno, M. A. et al. Molecular signature of Epstein-Barr virus infection in MS brain lesions. Neurol. Neuroimmunol. Neuroinflamm 5, e466 (2018).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"770_CR149","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00980-19","author":"B Serafini","year":"2019","unstructured":"Serafini, B., Rosicarelli, B., Veroni, C., Mazzola, G. A. & Aloisi, F. Epstein-Barr virus-specific CD8 T cells selectively infiltrate the brain in multiple sclerosis and interact locally with virus-infected cells: clue for a virus-driven immunopathological mechanism. J. Virol. https:\/\/doi.org\/10.1128\/JVI.00980-19 (2019).","journal-title":"J. Virol."},{"key":"770_CR150","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/nm1670","volume":"13","author":"M Recher","year":"2007","unstructured":"Recher, M. et al. Extralymphatic virus sanctuaries as a consequence of potent T-cell activation. Nat. Med. 13, 1316\u20131323 (2007).","journal-title":"Nat. Med."},{"key":"770_CR151","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1128\/JVI.78.10.5194-5204.2004","volume":"78","author":"D Hochberg","year":"2004","unstructured":"Hochberg, D. et al. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J. Virol. 78, 5194\u20135204 (2004).","journal-title":"J. Virol."},{"key":"770_CR152","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12974-015-0353-1","volume":"12","author":"C Veroni","year":"2015","unstructured":"Veroni, C. et al. Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis. J. Neuroinflamm. 12, 132 (2015).","journal-title":"J. Neuroinflamm."},{"key":"770_CR153","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/BF03210852","volume":"16","author":"T Kiriyama","year":"2010","unstructured":"Kiriyama, T., Kataoka, H., Kasai, T., Nonomura, A. & Ueno, S. Negative association of Epstein-Barr virus or herpes simplex virus-1 with tumefactive central nervous system inflammatory demyelinating disease. J. Neurovirol. 16, 466\u2013471 (2010).","journal-title":"J. Neurovirol."},{"key":"770_CR154","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0b013e3181d865a1","volume":"74","author":"SA Sargsyan","year":"2010","unstructured":"Sargsyan, S. A. et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 74, 1127\u20131135 (2010).","journal-title":"Neurology"},{"key":"770_CR155","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1093\/brain\/awp200","volume":"132","author":"SN Willis","year":"2009","unstructured":"Willis, S. N. et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 132, 3318\u20133328 (2009).","journal-title":"Brain"},{"key":"770_CR156","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp296","volume":"133","author":"LA Peferoen","year":"2010","unstructured":"Peferoen, L. A. et al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain 133, e137 (2010).","journal-title":"Brain"},{"key":"770_CR157","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1750-3639.2009.00343.x","volume":"20","author":"O Torkildsen","year":"2010","unstructured":"Torkildsen, O. et al. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathol. 20, 720\u2013729 (2010).","journal-title":"Brain Pathol."},{"key":"770_CR158","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1093\/brain\/awr197","volume":"134","author":"H Lassmann","year":"2011","unstructured":"Lassmann, H., Niedobitek, G., Aloisi, F., Middeldorp, J. M. & NeuroproMiSe EBV Working Group. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue\u2013report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain 134, 2772\u20132786 (2011).","journal-title":"Brain"},{"key":"770_CR159","first-page":"325","volume":"391","author":"AD Hislop","year":"2015","unstructured":"Hislop, A. D. & Taylor, G. S. T-cell responses to EBV. Curr. Top. Microbiol. Immunol. 391, 325\u2013353 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"770_CR160","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","volume":"25","author":"AD Hislop","year":"2007","unstructured":"Hislop, A. D., Taylor, G. S., Sauce, D. & Rickinson, A. B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25, 587\u2013617 (2007).","journal-title":"Annu. Rev. Immunol."},{"key":"770_CR161","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/1352458511408991","volume":"17","author":"KL Munger","year":"2011","unstructured":"Munger, K. L., Levin, L. I., O\u2019Reilly, E. J., Falk, K. I. & Ascherio, A. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult. Scler. 17, 1185\u20131193 (2011).","journal-title":"Mult. Scler."},{"key":"770_CR162","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1001\/jama.293.20.2496","volume":"293","author":"LI Levin","year":"2005","unstructured":"Levin, L. I. et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293, 2496\u20132500 (2005).","journal-title":"JAMA"},{"key":"770_CR163","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awl067","volume":"129","author":"JD Lunemann","year":"2006","unstructured":"Lunemann, J. D. et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 129, 1493\u20131506 (2006).","journal-title":"Brain"},{"key":"770_CR164","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature10251","volume":"476","author":"International Multiple Sclerosis Genetics Consortium","year":"2011","unstructured":"International Multiple Sclerosis Genetics Consortium. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214\u2013219 (2011).","journal-title":"Nature"},{"key":"770_CR165","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/brain\/awn108","volume":"131","author":"S Jilek","year":"2008","unstructured":"Jilek, S. et al. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 131, 1712\u20131721 (2008).","journal-title":"Brain"},{"key":"770_CR166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003220","volume":"9","author":"DF Angelini","year":"2013","unstructured":"Angelini, D. F. et al. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 9, e1003220 (2013).","journal-title":"PLoS Pathog."},{"key":"770_CR167","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1177\/1352458514536252","volume":"20","author":"MP Pender","year":"2014","unstructured":"Pender, M. P., Csurhes, P. A., Pfluger, C. M. & Burrows, S. R. Deficiency of CD8+ effector memory T cells is an early and persistent feature of multiple sclerosis. Mult. Scler. 20, 1825\u20131832 (2014).","journal-title":"Mult. Scler."},{"key":"770_CR168","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-11-95","volume":"11","author":"MP Pender","year":"2011","unstructured":"Pender, M. P., Csurhes, P. A., Pfluger, C. M. & Burrows, S. R. Decreased CD8+ T cell response to Epstein-Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes. BMC Neurol. 11, 95 (2011).","journal-title":"BMC Neurol."},{"key":"770_CR169","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jnnp-2011-300213","volume":"83","author":"MP Pender","year":"2012","unstructured":"Pender, M. P., Csurhes, P. A., Pfluger, C. M. & Burrows, S. R. CD8 T cell deficiency impairs control of Epstein\u2013Barr virus and worsens with age in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 83, 353\u2013354 (2012).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"770_CR170","doi-asserted-by":"publisher","first-page":"665718","DOI":"10.3389\/fimmu.2021.665718","volume":"12","author":"C Veroni","year":"2021","unstructured":"Veroni, C. & Aloisi, F. The CD8 T cell-Epstein-Barr virus-B cell trialogue: a central issue in multiple sclerosis pathogenesis. Front. Immunol. 12, 665718 (2021).","journal-title":"Front. Immunol."},{"key":"770_CR171","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/eji.202048739","volume":"51","author":"J van Langelaar","year":"2021","unstructured":"van Langelaar, J. et al. The association of Epstein-Barr virus infection with CXCR3+ B-cell development in multiple sclerosis: impact of immunotherapies. Eur. J. Immunol. 51, 626\u2013633 (2021).","journal-title":"Eur. J. Immunol."},{"key":"770_CR172","doi-asserted-by":"publisher","first-page":"E587","DOI":"10.1073\/pnas.1518130113","volume":"113","author":"SR Baglio","year":"2016","unstructured":"Baglio, S. R. et al. Sensing of latent EBV infection through exosomal transfer of 5\u2019pppRNA. Proc. Natl Acad. Sci. USA 113, E587\u2013E596 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"770_CR173","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062927","author":"A Afrasiabi","year":"2021","unstructured":"Afrasiabi, A. et al. The interaction of human and Epstein-Barr virus miRNAs with multiple sclerosis risk loci. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22062927 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"770_CR174","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s12195-016-0458-3","volume":"9","author":"CC Chen","year":"2016","unstructured":"Chen, C. C. et al. Elucidation of exosome migration across the blood\u2013brain barrier model in vitro. Cell. Mol. Bioeng. 9, 509\u2013529 (2016).","journal-title":"Cell. Mol. Bioeng."},{"key":"770_CR175","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.chom.2017.09.001","volume":"22","author":"S Jiang","year":"2017","unstructured":"Jiang, S. et al. The Epstein-Barr virus regulome in lymphoblastoid cells. Cell Host Microbe 22, 561\u2013573.e4 (2017).","journal-title":"Cell Host Microbe"},{"key":"770_CR176","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41588-018-0102-3","volume":"50","author":"JB Harley","year":"2018","unstructured":"Harley, J. B. et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat. Genet. 50, 699\u2013707 (2018).","journal-title":"Nat. Genet."},{"key":"770_CR177","doi-asserted-by":"publisher","DOI":"10.1101\/gr.264705.120","author":"T Hong","year":"2021","unstructured":"Hong, T. et al. Epstein-Barr virus nuclear antigen 2 extensively rewires the human chromatin landscape at autoimmune risk loci. Genome Res. https:\/\/doi.org\/10.1101\/gr.264705.120 (2021).","journal-title":"Genome Res."},{"key":"770_CR178","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0640-z","volume":"11","author":"A Afrasiabi","year":"2019","unstructured":"Afrasiabi, A. et al. Evidence from genome wide association studies implicates reduced control of Epstein-Barr virus infection in multiple sclerosis susceptibility. Genome Med. 11, 26 (2019).","journal-title":"Genome Med."},{"key":"770_CR179","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119605","volume":"10","author":"VA Ricigliano","year":"2015","unstructured":"Ricigliano, V. A. et al. EBNA2 binds to genomic intervals associated with multiple sclerosis and overlaps with vitamin D receptor occupancy. PLoS ONE 10, e0119605 (2015).","journal-title":"PLoS ONE"},{"key":"770_CR180","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1212\/WNL.0000000000001420","volume":"84","author":"R Mechelli","year":"2015","unstructured":"Mechelli, R. et al. Epstein-Barr virus genetic variants are associated with multiple sclerosis. Neurology 84, 1362\u20131368 (2015).","journal-title":"Neurology"},{"key":"770_CR181","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1177\/13524585211004422","volume":"27","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y. et al. Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibility loci. Mult. Scler. 27, 2141\u20132149 (2021).","journal-title":"Mult. Scler."},{"key":"770_CR182","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.biocel.2015.05.010","volume":"67","author":"S Ruhrmann","year":"2015","unstructured":"Ruhrmann, S., Stridh, P., Kular, L. & Jagodic, M. Genomic imprinting: a missing piece of the multiple sclerosis puzzle? Int. J. Biochem. Cell Biol. 67, 49\u201357 (2015).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"770_CR183","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/joim.13045","volume":"288","author":"L Kular","year":"2020","unstructured":"Kular, L. & Jagodic, M. Epigenetic insights into multiple sclerosis disease progression. J. Intern. Med. 288, 82\u2013102 (2020).","journal-title":"J. Intern. Med."},{"key":"770_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04732-5","volume":"9","author":"L Kular","year":"2018","unstructured":"Kular, L. et al. DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis. Nat. Commun. 9, 2397 (2018).","journal-title":"Nat. Commun."},{"key":"770_CR185","doi-asserted-by":"publisher","first-page":"769804","DOI":"10.3389\/fgene.2021.769804","volume":"12","author":"Y He","year":"2021","unstructured":"He, Y., Huang, L., Tang, Y., Yang, Z. & Han, Z. Genome-wide identification and analysis of splicing QTLs in multiple sclerosis by RNA-seq data. Front. Genet. 12, 769804 (2021).","journal-title":"Front. Genet."},{"key":"770_CR186","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.celrep.2017.01.020","volume":"18","author":"F Wanke","year":"2017","unstructured":"Wanke, F. et al. EBI2 is highly expressed in multiple sclerosis lesions and promotes early CNS migration of encephalitogenic CD4 T cells. Cell Rep. 18, 1270\u20131284 (2017).","journal-title":"Cell Rep."},{"key":"770_CR187","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coviro.2021.11.013","volume":"52","author":"R Guo","year":"2022","unstructured":"Guo, R. & Gewurz, B. E. Epigenetic control of the Epstein-Barr lifecycle. Curr. Opin. Virol. 52, 78\u201388 (2022).","journal-title":"Curr. Opin. Virol."},{"key":"770_CR188","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semcancer.2014.01.003","volume":"26","author":"I Tempera","year":"2014","unstructured":"Tempera, I. & Lieberman, P. M. Epigenetic regulation of EBV persistence and oncogenesis. Semin. Cancer Biol. 26, 22\u201329 (2014).","journal-title":"Semin. Cancer Biol."},{"key":"770_CR189","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12017-014-8298-6","volume":"17","author":"CI Kucukali","year":"2015","unstructured":"Kucukali, C. I., Kurtuncu, M., Coban, A., Cebi, M. & Tuzun, E. Epigenetics of multiple sclerosis: an updated review. Neuromol. Med. 17, 83\u201396 (2015).","journal-title":"Neuromol. Med."},{"key":"770_CR190","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009618","volume":"17","author":"SS Soldan","year":"2021","unstructured":"Soldan, S. S. et al. Epigenetic plasticity enables CNS-trafficking of EBV-infected B lymphocytes. PLoS Pathog. 17, e1009618 (2021).","journal-title":"PLoS Pathog."},{"key":"770_CR191","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4049\/jimmunol.156.1.371","volume":"156","author":"JM Greer","year":"1996","unstructured":"Greer, J. M. et al. Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein. J. Immunol. 156, 371\u2013379 (1996).","journal-title":"J. Immunol."},{"key":"770_CR192","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/eji.202048655","volume":"51","author":"H Zdimerova","year":"2021","unstructured":"Zdimerova, H. et al. Attenuated immune control of Epstein-Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15. Eur. J. Immunol. 51, 64\u201375 (2021).","journal-title":"Eur. J. Immunol."},{"key":"770_CR193","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1450-6","volume":"16","author":"S Agostini","year":"2018","unstructured":"Agostini, S. et al. HLA alleles modulate EBV viral load in multiple sclerosis. J. Transl. Med. 16, 80 (2018).","journal-title":"J. Transl. Med."},{"key":"770_CR194","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1212\/WNL.55.2.178","volume":"55","author":"K Wandinger","year":"2000","unstructured":"Wandinger, K. et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 55, 178\u2013184 (2000).","journal-title":"Neurology"},{"key":"770_CR195","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094497","volume":"9","author":"CE Cocuzza","year":"2014","unstructured":"Cocuzza, C. E. et al. Quantitative detection of Epstein-Barr virus DNA in cerebrospinal fluid and blood samples of patients with relapsing-remitting multiple sclerosis. PLoS ONE 9, e94497 (2014).","journal-title":"PLoS ONE"},{"key":"770_CR196","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/1352458508097920","volume":"15","author":"JW Lindsey","year":"2009","unstructured":"Lindsey, J. W., Hatfield, L. M., Crawford, M. P. & Patel, S. Quantitative PCR for Epstein-Barr virus DNA and RNA in multiple sclerosis. Mult. Scler. 15, 153\u2013158 (2009).","journal-title":"Mult. Scler."},{"key":"770_CR197","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1136\/jnnp.2004.048504","volume":"76","author":"D Buljevac","year":"2005","unstructured":"Buljevac, D. et al. Epstein-Barr virus and disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 76, 1377\u20131381 (2005).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"770_CR198","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jaut.2015.06.010","volume":"64","author":"JA Hollenbach","year":"2015","unstructured":"Hollenbach, J. A. & Oksenberg, J. R. The immunogenetics of multiple sclerosis: a comprehensive review. J. Autoimmun. 64, 13\u201325 (2015).","journal-title":"J. Autoimmun."},{"key":"770_CR199","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000656","author":"LS Enz","year":"2020","unstructured":"Enz, L. S. et al. Increased HLA-DR expression and cortical demyelination in MS links with HLA-DR15. Neurol. Neuroimmunol. Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000656 (2020).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"770_CR200","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.tig.2021.04.012","volume":"37","author":"R Martin","year":"2021","unstructured":"Martin, R., Sospedra, M., Eiermann, T. & Olsson, T. Multiple sclerosis: doubling down on MHC. Trends Genet. 37, 784\u2013797 (2021).","journal-title":"Trends Genet."},{"key":"770_CR201","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1002\/eji.202149179","volume":"51","author":"J Menegatti","year":"2021","unstructured":"Menegatti, J., Schub, D., Schafer, M., Grasser, F. A. & Ruprecht, K. HLA-DRB1*15:01 is a co-receptor for Epstein-Barr virus, linking genetic and environmental risk factors for multiple sclerosis. Eur. J. Immunol. 51, 2348\u20132350 (2021).","journal-title":"Eur. J. Immunol."},{"key":"770_CR202","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1212\/WNL.41.9.1349","volume":"41","author":"JA Burnham","year":"1991","unstructured":"Burnham, J. A., Wright, R. R., Dreisbach, J. & Murray, R. S. The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 41, 1349\u20131354 (1991).","journal-title":"Neurology"},{"key":"770_CR203","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","volume":"16","author":"D Baker","year":"2017","unstructured":"Baker, D., Marta, M., Pryce, G., Giovannoni, G. & Schmierer, K. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine 16, 41\u201350 (2017).","journal-title":"EBioMedicine"},{"key":"770_CR204","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","volume":"265","author":"B Ceronie","year":"2018","unstructured":"Ceronie, B. et al. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J. Neurol. 265, 1199\u20131209 (2018).","journal-title":"J. Neurol."},{"key":"770_CR205","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser, S. L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676\u2013688 (2008).","journal-title":"N. Engl. J. Med."},{"key":"770_CR206","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","volume":"378","author":"L Kappos","year":"2011","unstructured":"Kappos, L. et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378, 1779\u20131787 (2011).","journal-title":"Lancet"},{"key":"770_CR207","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","volume":"7","author":"BM Segal","year":"2008","unstructured":"Segal, B. M. et al. Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7, 796\u2013804 (2008).","journal-title":"Lancet Neurol."},{"key":"770_CR208","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","volume":"13","author":"L Kappos","year":"2014","unstructured":"Kappos, L. et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 13, 353\u2013363 (2014).","journal-title":"Lancet Neurol."},{"key":"770_CR209","doi-asserted-by":"publisher","first-page":"44266","DOI":"10.18632\/oncotarget.17863","volume":"8","author":"A Bilger","year":"2017","unstructured":"Bilger, A. et al. Leflunomide\/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication. Oncotarget 8, 44266\u201344280 (2017).","journal-title":"Oncotarget"},{"key":"770_CR210","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","volume":"119","author":"E Doubrovina","year":"2012","unstructured":"Doubrovina, E. et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119, 2644\u20132656 (2012).","journal-title":"Blood"},{"key":"770_CR211","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","volume":"115","author":"HE Heslop","year":"2010","unstructured":"Heslop, H. E. et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115, 925\u2013935 (2010).","journal-title":"Blood"},{"key":"770_CR212","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","volume":"108","author":"B Savoldo","year":"2006","unstructured":"Savoldo, B. et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108, 2942\u20132949 (2006).","journal-title":"Blood"},{"key":"770_CR213","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458514521888","volume":"20","author":"MP Pender","year":"2014","unstructured":"Pender, M. P. et al. Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Mult. Scler. 20, 1541\u20131544 (2014).","journal-title":"Mult. Scler."},{"key":"770_CR214","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124714","author":"MP Pender","year":"2018","unstructured":"Pender, M. P. et al. Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.124714 (2018).","journal-title":"JCI Insight"},{"key":"770_CR215","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.144624","author":"MP Pender","year":"2020","unstructured":"Pender, M. P. et al. Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.144624 (2020).","journal-title":"JCI Insight"},{"key":"770_CR216","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.87","volume":"6","author":"MP Pender","year":"2017","unstructured":"Pender, M. P., Csurhes, P. A., Burrows, J. M. & Burrows, S. R. Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis. Clin. Transl. Immunol. 6, e126 (2017).","journal-title":"Clin. Transl. Immunol."},{"issue":"(2_suppl.)","key":"770_CR217","first-page":"P638","volume":"27","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or, A. et al. Updated open-label extension clinical data and new magnetization transfer ratio imaging data from a phase I study of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherapy for progressive multiple sclerosis [ECTRIMS 2021 poster]. Multiple Sclerosis J. 27 (2_suppl.), P638 (2021).","journal-title":"Multiple Sclerosis J."},{"key":"770_CR218","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/BF00868517","volume":"243","author":"J Lycke","year":"1996","unstructured":"Lycke, J. et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J. Neurol. 243, 214\u2013224 (1996).","journal-title":"J. Neurol."},{"key":"770_CR219","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1212\/WNL.58.1.31","volume":"58","author":"E Bech","year":"2002","unstructured":"Bech, E. et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 58, 31\u201336 (2002).","journal-title":"Neurology"},{"key":"770_CR220","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1191\/1352458505ms1185oa","volume":"11","author":"JE Friedman","year":"2005","unstructured":"Friedman, J. E. et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult. Scler. 11, 286\u2013295 (2005).","journal-title":"Mult. Scler."},{"key":"770_CR221","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.cytogfr.2014.10.010","volume":"26","author":"V Annibali","year":"2015","unstructured":"Annibali, V. et al. IFN-beta and multiple sclerosis: from etiology to therapy and back. Cytokine Growth Factor. Rev. 26, 221\u2013228 (2015).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"770_CR222","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.virol.2010.03.014","volume":"402","author":"GL Bentz","year":"2010","unstructured":"Bentz, G. L., Liu, R., Hahn, A. M., Shackelford, J. & Pagano, J. S. Epstein-Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-beta. Virology 402, 121\u2013128 (2010).","journal-title":"Virology"},{"key":"770_CR223","doi-asserted-by":"publisher","first-page":"10040","DOI":"10.1128\/JVI.79.15.10040-10052.2005","volume":"79","author":"AM Hahn","year":"2005","unstructured":"Hahn, A. M., Huye, L. E., Ning, S., Webster-Cyriaque, J. & Pagano, J. S. Interferon regulatory factor 7 is negatively regulated by the Epstein-Barr virus immediate-early gene, BZLF-1. J. Virol. 79, 10040\u201310052 (2005).","journal-title":"J. Virol."},{"key":"770_CR224","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1586\/14787210.1.1.21","volume":"1","author":"E De Clercq","year":"2003","unstructured":"De Clercq, E. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. Expert Rev. Anti Infect. Ther. 1, 21\u201343 (2003).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"770_CR225","doi-asserted-by":"publisher","first-page":"12368","DOI":"10.1073\/pnas.2002392117","volume":"117","author":"NC Drosu","year":"2020","unstructured":"Drosu, N. C., Edelman, E. R. & Housman, D. E. Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase. Proc. Natl Acad. Sci. USA 117, 12368\u201312374 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"770_CR226","doi-asserted-by":"publisher","first-page":"102569","DOI":"10.1016\/j.msard.2020.102569","volume":"46","author":"O Torkildsen","year":"2020","unstructured":"Torkildsen, O., Myhr, K. M., Skogen, V., Steffensen, L. H. & Bjornevik, K. Tenofovir as a treatment option for multiple sclerosis. Mult. Scler. Relat. Disord. 46, 102569 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"770_CR227","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1128\/JVI.01409-07","volume":"82","author":"SL Elliott","year":"2008","unstructured":"Elliott, S. L. et al. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J. Virol. 82, 1448\u20131457 (2008).","journal-title":"J. Virol."},{"key":"770_CR228","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal, E. M. et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 196, 1749\u20131753 (2007).","journal-title":"J. Infect. Dis."},{"key":"770_CR229","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","volume":"25","author":"M Moutschen","year":"2007","unstructured":"Moutschen, M. et al. Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine healthy adults. Vaccine 25, 4697\u20134705 (2007).","journal-title":"Vaccine"},{"key":"770_CR230","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMra020100","volume":"347","author":"JF Bach","year":"2002","unstructured":"Bach, J. F. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347, 911\u2013920 (2002).","journal-title":"N. Engl. J. Med."},{"key":"770_CR231","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.msard.2017.02.019","volume":"14","author":"S Sheik-Ali","year":"2017","unstructured":"Sheik-Ali, S. Infectious mononucleosis and multiple sclerosis - updated review on associated risk. Mult. Scler. Relat. Disord. 14, 56\u201359 (2017).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"770_CR232","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1038\/sj.onc.1208367","volume":"24","author":"U Dirmeier","year":"2005","unstructured":"Dirmeier, U. et al. Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene 24, 1711\u20131717 (2005).","journal-title":"Oncogene"},{"key":"770_CR233","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11262-014-1101-9","volume":"49","author":"M Hussain","year":"2014","unstructured":"Hussain, M., Gatherer, D. & Wilson, J. B. Modelling the structure of full-length Epstein-Barr virus nuclear antigen 1. Virus Genes 49, 358\u2013372 (2014).","journal-title":"Virus Genes"}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41579-022-00770-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-022-00770-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-022-00770-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:34:14Z","timestamp":1733938454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41579-022-00770-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":233,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1038\/s41579-022-00770-5","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"27 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.M.L. founded and is an adviser to Vironika LLC. P.M.L. is named on a patent for inhibitors of EBNA1. S.S.S. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}